NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free ATXI Stock Alerts $0.13 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1450-Day Range$0.13▼$0.1952-Week Range$0.11▼$1.25Volume1.61 million shsAverage Volume4.50 million shsMarket Capitalization$5.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainability Get Avenue Therapeutics alerts: Email Address Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesApril 17, 2024 | americanbankingnews.comAvenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 9.7% in MarchApril 5, 2024 | msn.comSaks Fifth Avenue set to close at Fashion Mall at KeystoneApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 5, 2024 | msn.com2 suspects identified in connection with Euclid Avenue shooting: Mobile PoliceApril 5, 2024 | msn.comNew updates on revitalizations of Nashville’s 2nd Avenue years after Christmas Day bombingApril 5, 2024 | msn.comBurbank Man Found Deceased In Bus Shelter On Harlem AvenueApril 5, 2024 | msn.comDowntown Minneapolis' First Avenue N. corridor to get $30 million facelift, first big upgrade in decadesApril 5, 2024 | yahoo.comFatal crash shuts down I-43 southbound at Hampton Avenue for hoursApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 4, 2024 | msn.comTasing reported on Washington Avenue in North AvondaleApril 4, 2024 | msn.comHouse containing adults and child damaged by gunfire on Lyell AvenueApril 4, 2024 | msn.comPolice investigating school bus crash on Colerain Avenue in Mount AiryApril 3, 2024 | msn.comRoc Paint Division brings Boston artist for 'caring' mural at Avenue D R-CenterApril 3, 2024 | msn.comShooting reported on Glenwood Avenue in AvondaleApril 3, 2024 | msn.comWires reported down on Pennsylvania Avenue in York CityApril 3, 2024 | msn.comRecycling truck dumps smoldering load on Summit Avenue. A lithium battery was likely to blame.April 3, 2024 | yahoo.comMan connected to two Worth Avenue jewelry store smash and grabs is charged in a thirdApril 3, 2024 | msn.comVehicle crash reported on Tokay Avenue in ModestoApril 3, 2024 | msn.comJerome Avenue Bridge to temporarily close for reconstruction projectApril 3, 2024 | bizjournals.comLongtime Dallas bar Stoneleigh P preps for move to Lemmon Avenue from UptownApril 2, 2024 | yahoo.comNeighbors concerned by growing encampment near 8th Avenue and Navajo StreetApril 2, 2024 | msn.comLowry Avenue reconstruction project in northeast Minneapolis set to begin in mid-AprilApril 2, 2024 | msn.comFire causes heavy damage to Rockford home on Oakwood AvenueApril 2, 2024 | bizjournals.comProposed rezone on Watt Avenue in North Highlands would allow housing, retail on four different parcelsApril 2, 2024 | msn.comPete Buttigieg coming to Birmingham on Wednesday to celebrate $14.5 million grant for 4th AvenueApril 2, 2024 | msn.comBristol’s Randall Avenue Bridge Set for $2 Million MakeoverApril 2, 2024 | msn.comCLSA raises target price for Avenue Supermarts to Rs 5,514, second upgrade in a weekSee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/22/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-335.11% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book4.34Miscellaneous Outstanding Shares44,260,000Free Float43,464,000Market Cap$5.76 million OptionableNot Optionable Beta-0.24 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 56)CEO & Director Comp: $413.2kMr. David Jin (Age 33)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Xiaoqin Lu M.D. (Age 49)Consultant Comp: $1.05MDr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kMr. Srinivas Subramanian (Age 53)Executive Vice President More ExecutivesKey CompetitorsVaccinexNASDAQ:VCNXHoth TherapeuticsNASDAQ:HOTHProtagenic TherapeuticsNASDAQ:PTIXFirst Wave BioPharmaNASDAQ:FWBIXenetic BiosciencesNASDAQ:XBIOView All CompetitorsInsidersFortress Biotech, Inc.Bought 418,410 shares on 9/8/2023Total: $301,255.20 ($0.72/share)Lindsay A Md RosenwaldBought 348,675 shares on 9/8/2023Total: $251,046.00 ($0.72/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $0.1610 at the beginning of 2024. Since then, ATXI stock has decreased by 19.2% and is now trading at $0.1301. View the best growth stocks for 2024 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 283,100 shares, a drop of 9.7% from the March 15th total of 313,400 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is currently 0.1 days. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings results on Monday, March, 18th. The company reported $0.56 earnings per share (EPS) for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics's stock reverse split on the morning of Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
